The trial enrolled 685 patients with an average age of 68.4 years who needed pacemakers due to atrioventricular block. Of those, 57.5% were men. Seventeen centers in China, Hong Kong, the UK, the US, and Poland participated. Patients were randomly assigned in a 1:1 ratio to LBBP or RVP.
The study defined pacing-induced cardiomyopathy as an at least 10% reduction in left ventricular ejection fraction (LVEF) and a resultant LVEF of less than 50% with no other discernable cause of cardiomyopathy. The study population excluded patients with an LVEF of 36%-50% who were willing to have biventricular pacing and patients with implantable cardioverter-defibrillators. Analysis of echocardiograms was done in the core laboratory.